SeaX Ventures, a venture capital firm focusing on Southeast Asia, will continue investing in RyboDyn, a biotechnology startup based in the United States, as part of the latter’s $10 million seed funding round.

RyboDyn said in a release on Wednesday that the financing is intended to support the development of its artificial intelligence (AI)–powered platform. The platform can identify new therapeutic targets in cancer and  advance its early-stage programs toward clinical development.

The latest investment follows SeaX Ventures’ earlier participation as a co-lead investor in RyboDyn’s pre-seed round, signaling ongoing support for RyboDyn’s research approach. SeaX Ventures, with offices in Bangkok (Thailand) and Silicon Valley (the United States), invests in technology-focused startups across sectors including biotechnology, artificial intelligence, and energy.

RyboDyn’s work focuses on the “dark proteome,” referring to previously uncharacterized proteins that are not detectable through conventional sequencing technologies. Its platform combines non-canonical RNA analysis, proteomics, and artificial intelligence to detect and validate so-called “cryptic proteins” directly from patient tumor samples. These findings are compiled into a proprietary dataset designed to enable broader and repeatable discovery across multiple cancer types.

RyboDyn has demonstrated proof-of-concept in laboratory settings, including the use of antibody-drug conjugates to target cancer cells via newly identified proteins. This development contributed to the latest funding round.

Lunit to Be Featured in 21 AI Imaging Studies on Breast Cancer and Lung Disease at ECR 2026